Myriad to Co-market Sividon Breast Cancer Test | GenomeWeb

NEW YORK (GenomeWeb News) – Myriad Genetics GmbH and Sividon Diagnostics today announced a deal granting Myriad the exclusive rights to co-market Sividon's EndoPredict prognostic test kit for breast cancer patients outside the US.

The deal leverages Myriad's 45-person international commercial team and will "significantly increase" the number of medical specialists and sales professionals supporting EndoPredict, according to the companies.

Myriad Genetics GmbH is the international subsidiary of Myriad Genetics and is based in Zurich.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.